California Public Employees Retirement System Has $85.83 Million Stake in DexCom, Inc. (NASDAQ:DXCM)

California Public Employees Retirement System decreased its stake in DexCom, Inc. (NASDAQ:DXCM) by 3.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 691,682 shares of the medical device company’s stock after selling 25,161 shares during the quarter. California Public Employees Retirement System’s holdings in DexCom were worth $85,831,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Valley National Advisers Inc. boosted its stake in DexCom by 73.0% in the fourth quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company’s stock worth $30,000 after purchasing an additional 103 shares in the last quarter. MV Capital Management Inc. boosted its stake in DexCom by 99.3% in the fourth quarter. MV Capital Management Inc. now owns 277 shares of the medical device company’s stock worth $34,000 after purchasing an additional 138 shares in the last quarter. Washington Trust Advisors Inc. boosted its stake in DexCom by 120.6% in the fourth quarter. Washington Trust Advisors Inc. now owns 353 shares of the medical device company’s stock worth $44,000 after purchasing an additional 193 shares in the last quarter. NBC Securities Inc. acquired a new position in DexCom in the third quarter worth $47,000. Finally, Thompson Siegel & Walmsley LLC acquired a new position in DexCom in the third quarter worth $48,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Activity at DexCom

In other DexCom news, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the sale, the chief executive officer now directly owns 333,526 shares in the company, valued at $44,479,027.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other DexCom news, EVP Michael Jon Brown sold 2,624 shares of the stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $140.04, for a total value of $367,464.96. Following the completion of the sale, the executive vice president now directly owns 68,682 shares in the company, valued at $9,618,227.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 81,007 shares of the stock in a transaction dated Tuesday, March 12th. The stock was sold at an average price of $133.36, for a total value of $10,803,093.52. Following the completion of the sale, the chief executive officer now owns 333,526 shares of the company’s stock, valued at $44,479,027.36. The disclosure for this sale can be found here. Over the last quarter, insiders sold 189,375 shares of company stock worth $25,530,859. 0.41% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on DXCM shares. Royal Bank of Canada started coverage on DexCom in a research note on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price objective on the stock. Raymond James boosted their price objective on DexCom from $147.00 to $151.00 and gave the stock a “strong-buy” rating in a research note on Tuesday, January 23rd. UBS Group upped their price target on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, April 10th. Citigroup upped their price target on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Finally, StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research note on Tuesday. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $141.40.

DexCom Trading Up 2.9 %

NASDAQ DXCM opened at $137.87 on Thursday. The stock has a 50-day simple moving average of $130.58 and a 200 day simple moving average of $117.88. The company has a market capitalization of $54.60 billion, a PE ratio of 105.25, a P/E/G ratio of 2.30 and a beta of 1.20. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. DexCom, Inc. has a 12 month low of $74.75 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 8th. The medical device company reported $0.50 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.07. The business had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $1.02 billion. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The firm’s revenue was up 26.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.34 earnings per share. Research analysts forecast that DexCom, Inc. will post 1.76 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.